Fundación Gecp lung cancer research



#15CongressGECP

EGFR beyond Osimertinib

Dr. Enric Carcereny Medical Oncology Department. Catalan Institute of Oncology (ICO)-Badalona. Badalona-Applied Research Group in Oncology (B-ARGO) Badalona, Barcelona





Disclosures

Advisory / Consultancy : AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Roche, Takeda

Speaker Bureau / Expert testimony: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Pfizer, Roche, Takeda

Travel / Accommodation / Expenses : Bristol-Myers Squibb, Pfizer, Roche, Takeda














18

54


Introduction












Mok TS, et al. N Engl J Med 2017;376(7):629-40. Ramalingam SS, et al. N Engl J Med 2020;382(1):41-50.






Treatment strategies based on the resistance mechanisms







INSIGHT: Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial



PFS and OS were longer with tepotinib plus gefitinib than with chemotherapy in patients with high (IHC3+) MET overexpression n=34

- median PFS 8-3 months [4·1–16·6] vs 4-4 months [4·1–6·8]; HR 0·35, 0·17–0·74
- median OS 37-3 months [90% CI 24-2–37-3] vs 17-9 months [12-0–20-7]; HR 0-33, 0-14–0-76

Or MET amplification (mean gene copy number ≥5 or MET to centromere of chromosome 7 ratio ≥2) n=19


- median PFS 16-6 months [8-3–not estimable] vs 4-2 months [1-4– 7-0]; HR 0-13, 0-04–0-43
- median OS 37-3 months [90% CI not estimable] vs 13-1 months [3-25–not estimable]; HR 0-08, 0-01–0-51

Wu YL, et al Lancet Respir Med. 2020;8(11):1132-1143.







TATTON TRIAL: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer PFS







Hartmaier RJ, et al Cancer Discov. 2023;13(1):98-113.



Deat D. aslandshiril


Efficacy endpoints

	Part B: osimertinib 80 mg + savolitinib 600/300ª mg			Part D: osimertinib 80 mg + savolitinib 300 mg
	Previously treated with a 3G EGFR-TKI	No prior 3G EGFR-TKI, T790M- negative	No prior 3G EGFR-TKI, T790M-positive	No prior 3G EGFR-TKI, T790M-negative
Endpoint	n = 69	n=51	n=18	n = 42
ORR ⁶ , n (%)	23 (33)	33 (65)	12(67)	26 (62)
(95% CI)	(22-46)	(50-78)	(41-87)	(46-76)
Complete response	0	0	0	0
Partial response	23 (33)	33 (65)	12(67)	26 (62)
Stable disease ^c	29 (42)	12(24)	6 (33)	13(31)
Progressive disease	8(12)	3 (6)	0	1 (2)
Not evaluable	9(13)	3 (6)	0	2 (5)
Median PFS, months (95% CI)	5.5 (4.1-7.7)	9.1 (5.5-12.8)	11.1 (4.1-22.1)	9.0 (5.6-12.7)
Total PFS events, n (%)	51 (74)	36(71)	12(67)	29 (69)
PFS rate at 6 months, % (95% CI)	45 (32-57)	58 (43-71)	77 (49-90)	63 (45-76)
PFS rate at 12 months, % (95% CI)	21 (11-33)	38 (24-52)	47 (23-68)	38 (23-53)
Median DoR, months (95% CI)	9.5 (4.2-14.7)	10.7 (6.1-14.8)	11.0 (2.8-NC)	9.7 (4.5-14.3)
Median OS, ^d months (95% CI)	30.3 (11.8-NC)	18.8 (15.1-NC)	NC (24.4-NC)	NC (13-NC)
OS rate at 6 months, % (95% CI)	86 (74-93)	90 (77-96)	94 (65-99)	93 (79-98)
OS rate at 12 months, % (95% CI)	62 (47-73)	69 (52-81)	94 (65-99)	78 (61-88)
OS rate at 18 months, % (95% CI)	53 (38-66)	52 (36-67)	87 (58-97)	66 (49-79)






ORCHARD TRIAL Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy



Yu AH et al. ESMO 2021, #3222.

SAVANNAH: Phase II Trial of Osimertinib + Savolitinib in EGFR-Mutant, MET-Driven Advanced NSCLC, Following Prior Osimertinib

- Osimertinib + Savolitinib
- Progressed on prior osimertinib MET IHC3+ ≥50% and/or FISH GCN ≥5 or MET/CEP7 ratio ≥2



ORR 32% mDOR 8.3 m mPFS 5.3 m

Investigator assessment	With IHC90+ a status (nd/or FISH10+ N=108)	Without IHC90+ status	
	Total (N=108)	No prior CTx (n=87)	Total (N=77)	No prior CTx (n=63)
ORR (95% CI)	49% (39, 59)	52% (41, 63)	9% (4, 18)	10% (4, 20)
mDOR, months (95% Cl)	9.3 (7.6, 10.6)	9.6 (7.6, 14.9)	6.9 (4.1, 16.9)	7.3 (4.1 <i>,</i> NC)
mPFS, months (95% Cl)	7.1 (5.3, 8.0)	7.2 (4.7, 9.2)	2.8 (2.6,4.3)	2.8 (1.8, 4.2)

Ahn M-J et al. WCLC 2022. #EP08.02-140





INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance (n=122)

ORR

mDoR

mPFS

mOS

NE

- Tepotinib 500mg po QD + Osimertinib 80mg .
- Progressed on 1st line Osimertinib .
- FISH (MET GCN \geq 5 and/or MET/CEP7 \geq 2) ۰
- and/or liquid biopsy (MET plasma GCN \geq 2.3)
- 175 out of 451 patients (38.8%) were MET (+)

Tumor Shrinkage (n = 98*[†])

₹**₩**₽

*Excluded because baseline/postbaseline measurement unavailable (n = 4)


Best Overall Response

Partial response

Progressive disease

Stable disease

Not evaluable



80

60

40

20

-20

-40

-60

-80

-100

Change in Sum of Target Lesion Diameters (%)



ADC + EGFR TKI

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer

```
Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily)
```

Phase I/Ib. n=42


Patients with L858R or Del 19 EGFR mutation C-MET overexpressing

MET expression	N=25
Intermediate (25-49% cell MET IHC 3+)	11 (44%)
High (🛛 🗄 🕰 🍿 🍽 🎼 🏵 🗐 🕄	13 (52%)

Camidge DR et al Lung Cancer. J Clin Oncol. 2023;41(5):1105-1115.

Efficacy summary

	Teliso-V Plus Erlotinib			
Response	c-Met+ <i>EGFR</i> -M+ (n = 28), No./n (%)	c-Met+ <i>EGFR</i> -WT (n = 5), No./n (%)	c-Met+ <i>EGFR</i> -Rare/Unknown (n = 3), No./n (%)	Total (N = 36), No./N (%)
Best overall response ^a				
Complete response	1/28 (4)	0/5	0/3	1/36 (3)
Partial response	8/28 (29)	2/5 (40)	0/3	10/36 (28)
Stable disease	15/28 (54)	2/5 (40)	3/3 (100)	20/36 (56)
Progressive disease	4/28 (14)	1/5 (20)	0/3	5/36 (14)
Objective response rate ^b [95% CI]	9/28 (32.1) [15.9 to 52.4]	2/5 (40.0) [5.3 to 85.3]	0 [0.0 to 70.8]	11/36 (30.6) [16.3 to 48.1]
Disease control rate ^c [95% CI]	24/28 (85.7) [67.3 to 96.0]	4/5 (80.0) [28.4 to 99.5]	3/3 (100) [29.2 to 100]	31/36 (86.1) [70.5 to 95.3]
Progression-free survival				
Median, months [95% CI]	5.9 [2.8 to NR]	6.0 [1.2 to NR]	4.0 [1.6 to NR]	5.9 [2.8 to NR]








Chemotherapy + EGFR TKI

Comparison of gefitinib plus chemotherapy versus gefitinib alone: A meta analysis


Study ID	Study location	Rate of EGFR mutation	Type of tumor	Stage of cancer	Special type of population	Prospective and randomized	Combined treatment	Number of patients	Previous treatment
2007 Chen ¹⁶	China	50%	Lung adenocarcinoma	IV	None	Yes	Vinorelbine	48	previous chemotherapy with >= 2 regimens
2011 Chen ¹⁷	China	67%	Lung adenocarcinoma	IIIB/IV	None	Yes	Tegafur/Uracil	115	failed previous chemotherapy
2014 and 2015 Yang ^{19,24,a}	Asian multicentre	68%	NSCLC	IIIB/IV	Nonsmoker/Light former smoker	Yes	Pemetrexed + cisplatin	236	chemonaive
2016 An ²⁰	China	100%	NSCLC	IIIB/IV	None	Yes	Pemetrexed	90	N/A
2016 Cheng ²¹	Asian multicentre	100%	Nonsquamous NSCLC	IV/Recurrent	None	Yes	Pemetrexed	191	no prior systemic chemotherapy, immunotherapy, or biologic therap
2017 Han ²²	China	100%	Lung adenocarcinoma	IIIB/IV	None	Yes	Pemetrexed + Carboplatin	81	no prior systemic anticancer therapy for advanced disease
2019 Zhang ²⁵	China	100%	NSCLC	III/IV	None	No	Cisplatin	92	no prior surgery, chemotherapy, radi therapy, or immunotherapy
2019 Noronha ²⁶	India	100%	NSCLC	IIIB/IV	None	Yes	Pemetrexed + Carboplatin	334	N/A
2020 Hosomi ¹⁸	Japan	100%	Nonsquamous NSCLC	IIIB/IV/Recurrent	None	Yes	Pemetrexed + Carboplatin	341	no prior chemotherapy

^a The two studies by Yang et al. in 2014 and 2015 reported progression-free survival and overall survival of the same patient population, respectively. Thus, the two studies were considered as one in the present analysis. EGFR, Epidermal Growth Factor Receptor; NSCLC, Non-Small Cell Lung Cancer; N/A, Not Available.


ORR.



PFS




Grade <a>3 toxicity



HR=3.29 (95% CI 2.57–4.21; p < 0.001)


OS






Chemotherapy + EGFR TKI

FLAURA 2: Phase III trial osimertinib in combination with chemotherapy





PFS per investigator in patients with / without CNS metastases at baseline*



Progression-free survival per investigator

· Median PFS was improved by ~8.8 months with osimertinib plus platinum-pemetrexed vs osimertinib monotherapy





PFS2 and interim analysis of OS

 At DCO, 57 / 123 patients (46%) in the osimertinib plus platinum-pemetrexed arm and 91 / 151 patients (60%) in the osimertinib monotherapy arm received any subsequent anti-cancer treatment[†]

 In both arms, cytotoxic chemotherapy was the most common subsequent anti-cancer treatment (33% and 54% in the combination and monotherapy arms, respectively)[†]

Pasi A. Jänne et al WCLC 2023






Chemotherapy + EGFR TKI

FLAURA 2: Phase III trial osimertinib in combination with chemotherapy

Safety summary

- Median total duration of osimertinib exposure was 22.3 months (range 0.1c&3.8) in the osimertinib plus platinum-pemetrexed arm
 and 19.3 months (range 0.1c&3.8) in the osimertinib monotherapy arm
- In the combination arm patients received a median of 12 cycles of pemetrexed (range 1048) and 211 patients (76%) completed 4 cycles of platinum-based chemotherapy

Patients with AEs, n (%)*	Osimertinib + platinum-pemetrexed (n=276)	Osimertinib monotherapy (n=275)	
AE any cause	276 (100)	268 (97)	
Any AE ∉ আ 2000 🗉	176 (64)	75 (27)	
Any AE leading to death	18 (7)	8 (3)	
Any serious AE	104 (38)	53 (19)	
Any AE leading to discontinuation	132 (48)	17 (6)	
Osimertinib / carboplatin or cisplatin / pemetrexed discontinuation	30 (11) / 46 (17) / 119 (43)	17 (6) / NA / NA	
AE possibly causally related to treatment [†]	269 (97)	241 (88)	
Any AE 👌 🖪 🕮 🗍 🖩	146 (53)	29 (11)	
Causally related to osimertinib / carboplatin or cisplatin / pemetrexed	81 (29) / 104 (38) / 130 (47)	29 (11) / NA / NA	
Any AE leading to death	5 (2)	1 (<1)	
Causally related to osimertinib / carboplatin or cisplatin / pemetrexed	3 (1) / 2 (1) / 3 (1)	1 (<1) / NA / NA	
Any serious AE	52 (19)	15 (5)	



hematological toxicities, known to be associated with chemotherapy; there were no common Grade 4 AEs in the monotherapy arm

•Osimertinib in combination with platinum-pemetrexed has demonstrated a statistically significant and clinically meaningful improvement in PFS over osimertinib monotherapy in patients with EGFRm advanced NSCLC (HR: 0.62)

- Investigator-assessed median PFS: 25.5 vs 16.7 months (improvement of ~8.8 months)
- BICR-assessed median PFS: 29.4 vs 19.9 months (improvement of ~9.5 months)
- •PFS benefits were consistent across all pre-defined subgroups
- •PFS2 and OS data were immature at this interim analysis

•The safety profiles were as expected for each treatment and were manageable with standard medical practice

Pasi A. Jänne et al WCLC 2023





Consistent PFS

(8.2 vs 4.2 mo;

(8.3 vs 4.2 mo;

P<0.001b)

investigator: HR, 0.41

P<0.001b) & HR, 0.38


benefit by

Chemotherapy + EGFR-MET bispecific antibody


MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

0000

Study design




Primary Endpoint: Progression-free Survival by BICR



PFS Benefit across subgroups

ubgroup chemotherapy che Ill randomized patients uge category <65 years	Vors Hazard ratio emotherapy (95% CI) 0.48 (0.36–0.64)	Amivantamab- Chemotherapy	Chemotherap
secategory	0.48 (0.36-0.64)		
<65 years		74/131	171/263
	0.44 (0.31-0.64)	40/79	106/166
	0.61 (0.40-0.94)	34/52	65/97
Sex			
Female Hend	0.48 (0.33-0.68)	45/81	103/157
Male -	0.54 (0.35-0.84)	29/50	68/106
Race			
Asian Herei	0.58 (0.39-0.85)	39/63	82/127
Non-Asian	0.47 (0.32-0.71)	34/64	84/129
Veight category			
<80 kg	0.51 (0.38-0.68)	64/113	148/226
D-11286.	0.51 (0.23-1.11)	10/18	23/37
COG PS			
0	0.44 (0.28-0.69)	30/55	65/101
1 +••+	0.56 (0.39-0.79)	44/76	106/162
listory of smoking			
Yes Here I	0.45 (0.27-0.76)	19/41	61/95
No HOH	0.53 (0.38-0.74)	55/90	110/168
listory of brain metastases			
Yes Hereit	0.52 (0.35-0.78)	34/58	79/120
No Herei I	0.48 (0.33-0.70)	40/73	92/143
Dsimertinib line of therapy			
First-line	0.47 (0.34-0.66)	54/97	117/181
Second-line	0.55 (0.32-0.93)	20/34	54/82
EGFR mutation			
Ex19del	0.60 (0.44-0.83)	58/89	118/183
L858R	0.30 (0.17-0.54)	16/42	53/79



During the study, the IDMC identified increased hematologic toxicities in the amivantamablazertinib-chemotherapya arm

•The amivantamab-lazertinib-chemotherapy regimen was modified to start lazertinib after carboplatin completion






Chemotherapy + EGFR-MET bispecific antibody

MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib


ORR ans **DoR**




BICR-assessed Response, n (%) ^b	Chemotherapy (n=263)	Amivantamab- Chemotherapy (n=131)	Amivantamab- Lazertinib- Chemotherapy (n=263)
Best Response			
CR	1 (0.4)	2 (2)	6 (2)
PR	93 (36)	81 (62)	157 (61)
SD	82 (32)	30 (23)	61 (24)
PD	52 (20)	10 (8)	14 (5)
NE/UNK	32 (12)	7 (5)	21 (8)
Median DoR ^c	5.6 mo (95% Cl, 4.2–9.6)	6.9 mo (95% CI, 5.5–NE)	9.4 mo (95% Cl, 6.9–NE)

Passaro A et al ESMO 2023

Intracranial Progression-free Survival by BICR



Intracranial Progression-free Survival by BICR Among Patients With a History of Brain Metastases and No Prior Brain Radiotherapy








Chemotherapy + EGFR-MET bispecific antibody

MARIPOSA-2, a Phase 3, Global, Randomized, Controlled Trial Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

Early Interim Overall Survival



At time of data cutoff, the median follow-up for the study was 8.7 months

Passaro A et al ESMO 2023

Summary of Adverse Events (AEs)

	Chemotherapy (n=243)	Amivantamab- Chemotherapy (n=130)	Amivantamab-Lazertinib- Chemotherapy ^a (n=263)
Treatment duration, median (range)	3.7 months (0–15.9)	6.3 months (0–14.7)	5.7 months (0.1–18.6)
No. of chemotherapy cycles, median (range)			
Carboplatin	4 (1–5)	4 (1–4)	4 (1–4)
Pemetrexed	6 (1–23)	9 (1–22)	7 (1–25)
TEAE, n (%)	Chemotherapy (n=243)	Amivantamab- Chemotherapy (n=130)	Amivantamab-Lazertinib- Chemotherapy ^a (n=263)
Any AEs	227 (93)	130 (100)	263 (100)
4 IIII 🖉 🖘	117 (48)	94 (72)	242 (92)
Serious AEs	49 (20)	42 (32)	137 (52)
AEs leading to death	3 (1)	3 (2)	14 (5)
Any AE leading to treatment:			
Interruptions of any agent	81 (33)	84 (65)	202 (77)
Reductions of any agent	37 (15)	53 (41)	171 (65)
Discontinuations of any agent	9 (4)	24 (18)	90 (34)
Discontinuations of all agents due to AE	10 (4)	14 (11)	38 (14)

· Median treatment duration was longer for the amivantamab- containing arms vs chemotherapy

- Amivantamab-containing arms had higher rates of grade ≥3 AEs and dose modifications vs chemotherapy
- · Aes leading to death were low

• Discontinuations of all agents due to treatment- related AEs was 2%, 8%, and 10%





EGFR-MET bispecific antibody + EGFR TKI

CHRYSALIS-2: Amivantamab and lazertinib in patients with EGFRmutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy

 $\label{eq:amplitude} \textbf{Amivantamab} \text{ is an EGFR-MET bispecific antibody with immune cell-directing} \\ activity$

Lazertinib is a CNS-penetrant, 3rd-generation EGFR TKI with efficacy in activating *EGFR* mutations, T790M, and brain metastases

Study design

RYSALIS-2 (ClinicalTrails.gov Ide dy Design

Dose Expansion Cohorts RP2CD: Lazertinib 240 mg PO + Amivantamab 1050 mg (1400 mg for ≥80 kg) IV


Cohort A: EGFR ex19del or L858R

Post-osimertinib and platinum-based chemotherapy (n=162)

Cohort D. COED av00in

Shu C et al ASCO 2022

Best antitumt response and ORR



CNS antitumor activity

yoio

Best CNS Lesion Assessment/evaluation	Untreated Brain Metastases (n=27)
Complete clearance ("absent")	7 (26%)
Non-CR/non-PR ("present")	20 (74%)
Progressive disease ("unequivocal progression")	0





EGFR-MET bispecific antibody + EGFR TKI + chemotherapy

N=20

CHRYSALIS-2: Amivantamab and lazertinib in patients with EGFRmutant non-small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy

Study design



Cohort B: EGFR ex20ins^b


Post-standard of care and platinum-based chemothera

Cohort C: Uncommon EGFR mutations^b

CHRYSALIS-2 (NCT04077463)

	Dosing (21-day	Dosing (21-day cycle)			
Eligibility	Lazertinib	240 mg daily			
EGFR-mutated, advanced NSCLC post-TKI (max of	Amivantamab	1400/1750 ^b mg on C1 D1/D2, C1D8, C1D15, C2D1; 1750/2100 ^b mg C3+ Q3W			
3 prior lines)	Chamatharan	Carboplatin (AUC5; stopped after 4 cycles)			
	Chemotherapy	Pemetrexed (500 mg/m ²) until disease progression			
Endpoints					

Overall Response Rate




Investigator-assessed response (n=20)					
ORR	50% (95% Cl, 27∞ ₮ 3)				
Median DOR	Not estimable				
Ongoing response	8 of 10 responders				
◈ोेः।ऽО∎♥३	8 of 10 responders				
CBR ^b	80% (95% CI, 56c%)				

- At median follow-up of 13.1 months, 11 (55%) patients remain on treatment
- 3 of 7 patients with SD as best response had SD duration >6 m, 2 of which remain on treatment
- A total of 5 patients were treated beyond progression with increment median treatment duration after progression of 4.2 m





EGFR-MET bispecific antibody + EGFR TKI + chemotherapy *CHRYSALIS-2*



Se-Hoon Lee et al WCLC 2023





EGFR-MET bispecific antibody + EGFR TKI + chemotherapy

CHRYSALIS-2

SAFETY PROFILE

	Total ^a			
Associated with EGFR inhibition				
Rash	15 (75)	1 (5)		
Paronychia	12 (60)	0		
Stomatitis	12 (60)	0		
Dermatitis acneiform	8 (40)	2 (10)		
Diarrhea	6 (30)	1 (5)		
Associated with MET inhibition				
Hypoalbuminemia	8 (40)	2 (10)		
Other				
Neutropenia	18 (90)	14 (70)		
IRR	13 (65)	0		
Fatigue	10 (50)	5 (25)		
Nausea	10 (50)	0		
COVID-19	8 (40)	0		
Thrombocytopenia	8 (40)	5 (25)		
Constipation	7 (35)	0		
Decreased appetite	7 (35)	1 (5)		
Leukopenia	7 (35)	4 (20)		
Alanine aminotransferase increased	6 (30)	0		
Anemia	6 (30)	2 (10)		
Pulmonary embolism	6 (30)	1 (5)		
Aspartate aminotransferase increased	5 (25)	0		
Back pain	5 (25)	0		
Epistaxis	5 (25)	0		
Hemorrhoids	5 (25)	0		
Peripheral sensory neuropathy	5 (25)	0		

As of November 15, 2022, the median follow-up was 13.1 months
Safety profile was consistent with that of individual components; no new safety signals, with most AEs at grade 1-2
Median treatment cycles was 15.5 (range, 2–23)
Median number of cycles of carboplatin and pemetrexed were 3.5 and 9.5, respectively

Efficacy according to MET expression

- ORR: 30%
- Median PFS: 5.7 months
- Median DoR: 10.8 months

	MET+ (n=28)	MET- (n=49)
ORR	61% (95% Cl, 41–79)	14% (95% CI, 6–27)
Median DOR	10.8 months (95% CI, 2.9–NE)	6.8 months (95% CI, 1.9–NE)
CBR ^a	86% (95% Cl, 67–96)	61% (95% CI, 46–75)
Median PFS	12.2 months (95% CI, 8.0–NE)	4.2 months (95% CI, 2.8–6.4)

MET 3+ staining on DEPA Extumor cells was identified as predictive of response A total of 28 of 77 (36%) patients had MET 3+

Se-Hoon Lee et al WCLC 2023






Byyoung Chul Cho et al ESMO 2023

EGFR-MET bispecific antibody + EGFR TKI

MARIPOSA: Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC

Study design




MARIPOSA (ClinicalTrials.gov Identifier: NCT04487080) enrollment period: November 2020 to May 2022; data cut-off: 11-Aug-2023.


**Simple (20) 60% Structure CT scans. Brain scan frequency was every 8 weeks for the first 30 months and then every 12 weeks thereafter for patients with a history of brain metastasis. Extracranial tumor assessments were conducted every 8 weeks for the first 30 months and then every 12 weeks indicates on a construction of the scans. Brain scans frequency was every 8 weeks for patients with no history of brain metastasis. Extracranial tumor assessments were conducted every 8 weeks for the first 30 months and then every 12 weeks indicates on a construction by BICR.

¹⁶Key statistical assumptions: 800 patients with 450 PFS events would provide approximately 90% power for anivantamab + lazertinib vs osimertinib to detect a HR of 0.73 using a log-rank test, with an overall two-sided apha of 0.05 (assuming an incremental median PFS of 7 months). Statistical hypothesis testing included PFS and then OS. "These secondrave monotonist (swindmedian in diring and in the 1 a future concernses."

Lazertinib Monotherapy Demonstrates Meaningful Clinical Activity




Primary Endpoint: Progression-free Survival by BICRa



Amivantamab + lazertinib reduced the risk of progression or death by 30% and improved median PFS by 7.1 months

Extracranial Progression-free Survival by BICRa








EGFR-MET bispecific antibody + EGFR TKI

MARIPOSA: Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC


PFS Benefit Seen Across Predefined Subgroups

			Events/N	
Subgroup Amivantamab + L	Favors Favors Lazertinib	HR (95% CI)	Amivantamab + Lazertinib	Osimertinib
All randomized patients	H O H	0.70 (0.58–0.85)	192/429	252/429
Age category <65 years	⊢●⊣	0.50 (0.39-0.65)	94/235	153/237
		1.06 (0.80-1.41)	98/194	99/192
<75 years	HeH I	0.70 (0.57-0.85)	165/378	220/376
1 🛲 ALC		0.77 (0.46-1.30)	27/51	32/53
Sex		- (
Female	⊢ ● -	0.70 (0.55-0.90)	112/275	140/251
Male	⊢ ●{	0.74 (0.55-0.98)	80/154	112/178
Race		· · · ·		
Asian		0.67 (0.52-0.86)	105/250	144/251
Non-Asian	- -	0.75 (0.56-0.99)	85/117	108/177
Weight category		· · · ·		
<80 kg		0.70 (0.57-0.86)	161/376	209/368
□~£_2%	⊢ − ● <u>+</u> -	0.77 (0.48-1.22)	31/53	43/61
ECOG PS		· · · ·		
0	⊢ ● <u>+</u>	0.79 (0.56-1.12)	56/141	76/149
1	HI I	0.66 (0.52-0.82)	136/288	176/280
History of smoking				
Yes	⊢ ● ¦I	0.78 (0.56-1.08)	67/130	79/134
No	⊢●┥	0.67 (0.53-0.84)	125/299	173/295
History of brain metastases		· · · ·		
Yes	⊢●⊣	0.69 (0.53-0.92)	94/178	111/172
No	H H	0.69 (0.53-0.89)	98/251	141/257
EGFR mutation		/		
Ex19del		0.65 (0.51-0.85)	101/257	142/257
L858R	⊢● -}	0.78 (0.59-1.02)	90/171	110/172
0.1	1 10	. ,		

Consistent PFS (BICR) Benefit With or Without Brain Metastases



ORR and DoR by BICR



Byyoung Chul Cho et al ESMO 2023

Amivantamab + lazertinib improved median DoR by 9 months, suggesting longer time to resistance and


progression





EGFR-MET bispecific antibody + EGFR TKI

MARIPOSA: Amivantamab Plus Lazertinib Versus Osimertinib as First-line Treatment in EGFR-mutated Advanced NSCLC Interim Overall Survival



409 395 372 349 280 186 110 Osimertinib 429 416

- •VTE rates were higher for amivantamab + lazertinib
 - Most common preferred terms were pulmonary embolism and deep vein thrombosis
 - Most VTEs were grade 1-2 .
 - Incidence of grade 4-5 VTEs was low (<1%)
 - and comparable between arms

Safety Profile

by preferred term, n (%) Related to EGFR Paronvchia 0.5% inhibition Rash 1% Diarrhea 2% 27% Dermatitis acneiform Stomatitis 0.2% Pruritus 0.5% 0.2% Hypoalbuminemia 43% Related to MET inhibition Peripheral edema 2% 34% IRR ٠ Other ALT increased Constipation AST increased 25% COVID-19 2% Decreased appetite Anemia Nausea Amivantamab + Lazertinib: grade 1-2 0.2% Hypocalcemia Osimertinib: grade 1-2 Cough 50% 0% 100% 50%

Byyoung Chul Cho et al ESMO 2023

- Safety profile of amivantamab + lazertinib was consistent with prior reports, mostly grades 1-2
- EGFR- and MET-related AEs were higher for amivantamab + lazertinib except diarrhea, which was higher for osimertinib
- Incidence of grade 4-5 AEs was low and comparable between arms
- Rates of ILD/pneumonitis remained low, at ~3% for both arms

100%

•Safety profile of amivantamab + lazertinib was consistent with prior reports, mostly grades 1-2 •EGFR- and MET-related AEs were higher for amivantamab + lazertinib except diarrhea, which was higher for osimertinib


•Incidence of grade 4-5 AEs was low and comparable between arms •Rates of ILD/pneumonitis remained low, at ~3% for both arms





Antiangiogenic drugs + EGFR TKI

Beverly trial Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC



mPFS: 16 vs 9,7m; p=0,0015
mPFS: 17,9 vs 13,5m; p=0,33
mPFS: 9,4 vs 13,5m; p=0,20

mPFS: 20,2 vs 22,1m; p=0,213

Maemondo M, et al. J Clin Oncol 2020;38:9506. Akamatsu H, et al. Jama Oncol 2021;7:386. Nakagawa K, et al. Lancet Oncol 2019;20:1655-69. Piccirillo MC, et al. ESMO 2021 (Abstr 12070).

Overall Survival

Progression Free Survival.

Erlotinib


Erlotinib + BEV

36

30

42 48 54


60








Antiangiogenic drugs + EGFR TKI



Progression Free Survival







To wrap up...

- Chemotherapy combined with EGFR inhibition and EGFR-MET bispecific antibody + EGFR TKI, while awaiting overall survival data, represents a novel standard in first-line treatment.
- EGFR TKIs will remain the primary treatment for a significant proportion of patients with EGFR gene mutations.
- After first-line treatment of EGFR-mutated patients, exploring clinical trials for selective MET inhibitors or antibody-drug conjugates (ADCs) targeting the MET pathway in cases of MET overexpression could be considered. For patients previously treated with EGFR-MET bispecific antibody in the first line, uncertainties might arise regarding subsequent steps or treatments in their medical care pathway.
- Prioritizing research on anti-angiogenic drugs, especially in combination with emerging treatments, should continue in the management of EGFR gene mutation patients

Fundación Gecp lung cancer research



#15CongressGECP

"Algunas veces hay que decidirse entre una cosa a la que se está acostumbrado y otra que nos gustaría conocer."

Paulo Coelho

Muchas Gracias